mRNA Vaccines and RNAi Therapeutics Market Size, Share, Competitive Landscape and Trend Analysis Report, by Disease Type, by Route of administration, by End user : Global Opportunity Analysis and Industry Forecast, 2021-2031

mRNA Vaccines and RNAi Therapeutics Market Research, 2031

The global mRNA vaccines and RNAi therapeutics market was valued at $707.97 million in 2021, and is projected to reach $12.31 billion by 2031, growing at a CAGR of 31.3% from 2022 to 2031. Messenger Ribonucleic Acid (mRNA) refers to a single protein-coding gene in the genome that acts as a basis for protein synthesis within the cells. mRNA vaccines and RNAi therapeutics combine the desirable immunological properties and are prepared in laboratories using mammalian cells. Some of the common types of vaccines and therapeutics include self-amplifying, non-replicating, in vivo self-replicating and in vitro dendritic cell non-replicating mRNA. They are injected into the body to trigger virus-detecting immune sensors and produce viral antigen proteins within the cells. This aids in enhancing the body’s immunity by improving B- and T-cell responses.

mRNA vaccines and RNAi therapeutics market size is anticipated to increase globally during the forecast period, owing to increase in prevalence of chronic disease and infectious disease, initiatives taken by government for large scale sequencing projects. Moreover, target specialty and selectivity of treatment and increase in awareness about vaccination are some mRNA vaccines and RNAi therapeutics market trends which further drive mRNA vaccines and RNAi therapeutics market growth. However, high cost of research, threat of failure and challenges in quantification of mRNA are anticipated to hamper the market growth. Conversely, application of mRNA technology and development of mRNA biomarker is expected to offer lucrative mRNA vaccines and RNAi therapeutics market opportunity for the key player in the market.

COVID-19 Impact Analysis
Coronavirus (COVID-19) was discovered in December 2019, in Hubei province of Wuhan city in China. A virus, severe acute respiratory syndrome coronavirus 2, causes the disease (SARS-CoV-2), which is transmitted among humans. 
The disease rapidly spread to other parts of the globe post its discovery in Wuhan. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization declared it as a pandemic. In addition, there are only a few vaccines that received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to limit the spread of this disease. Furthermore, to maintain social distancing in various countries across the globe have led to adoption of lockdowns. 

The COVID-19 pandemic has positively impacted the mRNA vaccines industry and RNAi therapeutics industry, owing to mRNA vaccines are promising next-generation vaccines that have introduced a new age in vaccinology. The recent approval of two COVID-19 mRNA vaccines (mRNA-1273 and BNT162b2) has accelerated mRNA vaccine technology and boosted the pharmaceutical and biotechnology industry. These mRNA vaccines are expected to help to tackle COVID-19 pandemic through immunization, offering considerable hope for future mRNA vaccines. Human trials with data both from mRNA cancer vaccines and mRNA infectious disease vaccines have provided encouraging results, inspiring the pharmaceutical and biotechnology industries to focus on this area of research.

Furthermore, in mRNA vaccines market, mRNA-based COVID-19 vaccines are a more promising choice compared to conventional vaccine strategies as mRNA vaccine candidates have the capacity for rapid development with high effectiveness which further fuel growth of thse products during mRNA vaccines and RNAi therapeutics market forecast. These vaccines also have the potential for low-cost manufacturing and safer administration. Therefore, mRNA vaccines have revolutionized the vaccinology field by addressing all the current challenges in mRNA vaccines market.

Global mRNA Vaccine and RNAi Therapeutics Market Segmentation

The mRNA vaccine and therapeutics market is segmented on the basis of disease type, route of administration, end user and region. On the basis of disease type, the market is classified into hereditary transthyretin-mediated amyloidosis genetic, acute hepatic porphyria, primary hyperoxaluria type 1 and Atherosclerotic cardiovascular disease. On the basis of route of administration, it is segmented into IV infusion and subcutaneous. On the basis of end user, it categorized into research institute and hospitals and clinics. Furthermore, on the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Global mRNA Vaccine and RNAi Therapeutics Market by Disease Type
By disease type, the mRNA vaccine and RNAi therapeutics market are divided into hereditary transthyretin-mediated amyloidosis genetic, acute hepatic porphyria, primary hyperoxaluria type 1 and Atherosclerotic cardiovascular disease. The Hereditary transthyretin-mediated amyloidosis genetic segment was the major revenue contributor in mRNA vaccines and RNAi therapeutics market share, and is anticipated to continue this trend during the forecast period, owing to rise in demand for the treatment of ATTR amyloidosis owing to the increasing prevalence and increasing need for the treatment of fatal disease. In addition, increase in awareness, improvement in diagnostic procedures, improvement in healthcare services, rapid economic growth in developing countries, and rise in R&D activities further boost the market growth. On the other side, atherosclerotic cardiovascular disease is projected to exhibit the fastest market growth during the forecast period, owing to high consumption of cholesterol-lowering drugs by patients to reduce blockages in arteries further boost growth of the mRNA vaccines and RNAi therapeutics market size.

Global mRNA Vaccine and RNAi Therapeutics Market by Route of Administration
By route of administration, the market is divided into IV infusion and Subcutaneous. The IV infusion segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the forecast period, owing to increase in adoption of IV infusion for administration of vaccines and therapeutics. On the other side, subcutaneous segment is projected to exhibit the fastest market growth during the forecast period owing to cost effectiveness of subcutaneous route of administration as compare to IV infusion.

Global mRNA Vaccine and RNAi Therapeutics Market by End User
By end user, the market is divided into research institute and hospitals and clinics.  The hospitals and clinics segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the forecast period, owing to increase in number of patients with respiratory disease, cancer and infectious disease.

Global mRNA Vaccine and RNAi Therapeutics Market by region
By region, the mRNA vaccine and therapeutics market are analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2021, accounting for the highest share, and is anticipated to maintain this trend during the forecast period. Moreover, rise in well-established healthcare system, increase in number of geriatric patients and supportive reimbursement policies in healthcare system propel the market growth. On the other side, Asia-Pacific is projected to exhibit the fastest market growth during the forecast period owing to, increase in prevalence of chronic diseases and increase in need of mRNA vaccine and RNAi therapeutics for treatment of such diseases.

The major companies profiled in the report include Alnylam Pharmaceuticals, BioNTech AG, CureVac AG, eTheRNA Immunotherapy, Ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamon therapeutic Inc., Sanofi AG, SCM Lifescience Co., Ltd, Sarepta Therapeutics, Arcturus Therapeutics, Ionis pharmaceuticals Inc., Nutcracker Therapeutics, TIBA Biotech.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mRNA vaccines and RNAi therapeutics market analysis from 2021 to 2031 to identify the prevailing mrna vaccines and rnai therapeutics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the mRNA vaccines and RNAi therapeutics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global mRNA vaccines and RNAi therapeutics market trends, key players, market segments, application areas, and market growth strategies.

  mRNA Vaccines and RNAi Therapeutics Market Report Highlights

Aspects	Details
By Disease Type	Hereditary transthyretin-mediated amyloidosis genetic Acute hepatic porphyria Primary hyperoxaluria type 1 Atherosclerotic cardiovascular disease
By Route of administration	IV infusion Subcutaneous
By End user	Research Institutes Hospitals and clinics
By Region	North America  (U.S., Canada, Mexico) Europe  (Germany, France, U.K., Italy, Spain, Rest of Europe) Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players	Sanofi AG, SCM Life Sciences (Argos Therapeutics, Inc. ), Arcturus Therapeutics, Curevac AG, Tiba Biotech, Sarepta Therapeutics, Moderna Therapeutics, Etherna Immunotherapies, Ethris GMBH, BioNTech AG, Sangamo Therapeutics, Inc., Ionis Pharmaceuticals, Inc, Alnylam Pharmaceuticals, IN-CELL-ART, Nutcracker

Analyst Review

Large number of research projects are undertaken to prove the therapeutic and diagnostic potential of mRNAs which in turn is expected to stimulate the demand of mRNA vaccines and therapeutics. In addition, increase in prevalence of chronic disease and infectious disease and initiatives taken by government for large scale sequencing projects is further expected to boost the market growth. The mRNA vaccines and therapeutics market has piqued the interest of healthcare professionals and researchers, owing to its therapeutic and diagnostic potential.
Furthermore, increase in funding by various government and private organizations is expected to drive the mRNA vaccines and therapeutics market. Moreover, the recent trend of outsourcing to CROs which provides the expression analysis and quantitative services for mRNA research has further boosted the market growth. However, computational challenges such as inaccurate results in knowing the desired target sequences are expected to hamper the market growth. The mRNA research is the highest in North American region, owing to heavy expenditure by the government on research and experiments. It is followed by Europe and Asia-Pacific, respectively.
 

Author Name(s) : Monika Darandale | Roshan Deshmukh

Related Tags

• Molecular Biology
• Genomic Technologies
• Cardiology